174 related articles for article (PubMed ID: 34647140)
21. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark.
Roze S; de Portu S; Smith-Palmer J; Delbaere A; Valentine W; Ridderstråle M
Diabetes Res Clin Pract; 2017 Jun; 128():6-14. PubMed ID: 28432898
[TBL] [Abstract][Full Text] [Related]
22. Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes.
Spaic T; Driscoll M; Raghinaru D; Buckingham BA; Wilson DM; Clinton P; Chase HP; Maahs DM; Forlenza GP; Jost E; Hramiak I; Paul T; Bequette BW; Cameron F; Beck RW; Kollman C; Lum JW; Ly TT;
Diabetes Care; 2017 Mar; 40(3):359-366. PubMed ID: 28100606
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
[TBL] [Abstract][Full Text] [Related]
24. Analysis of glucose responses to automated insulin suspension with sensor-augmented pump therapy.
Ly TT; Nicholas JA; Retterath A; Davis EA; Jones TW
Diabetes Care; 2012 Jul; 35(7):1462-5. PubMed ID: 22584133
[TBL] [Abstract][Full Text] [Related]
25. Hybrid Close-Loop Systems Versus Predictive Low-Glucose Suspend and Sensor-Augmented Pump Therapy in Patients With Type 1 Diabetes: A Single-Center Cohort Study.
Lunati ME; Morpurgo PS; Rossi A; Gandolfi A; Cogliati I; Bolla AM; Plebani L; Vallone L; Montefusco L; Pastore I; Cimino V; Argenti S; Volpi G; Zuccotti GV; Fiorina P
Front Endocrinol (Lausanne); 2022; 13():816599. PubMed ID: 35498423
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes.
Calhoun PM; Buckingham BA; Maahs DM; Hramiak I; Wilson DM; Aye T; Clinton P; Chase P; Messer L; Kollman C; Beck RW; Lum J;
J Diabetes Sci Technol; 2016 Nov; 10(6):1216-1221. PubMed ID: 27207890
[TBL] [Abstract][Full Text] [Related]
27. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk.
Choudhary P; Shin J; Wang Y; Evans ML; Hammond PJ; Kerr D; Shaw JA; Pickup JC; Amiel SA
Diabetes Care; 2011 Sep; 34(9):2023-5. PubMed ID: 21868778
[TBL] [Abstract][Full Text] [Related]
28. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
[TBL] [Abstract][Full Text] [Related]
29. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
[No Abstract] [Full Text] [Related]
30. Real-world outcomes with different technology modalities in type 1 diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1845-1850. PubMed ID: 33838993
[TBL] [Abstract][Full Text] [Related]
31. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes.
Ly TT; Brnabic AJ; Eggleston A; Kolivos A; McBride ME; Schrover R; Jones TW
Value Health; 2014 Jul; 17(5):561-9. PubMed ID: 25128049
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in older adults: A retrospective study in Bogota, Colombia.
Morros-González E; Gómez AM; Henao Carrillo DC; Ursida V; Serrano S; Rondón Sepúlveda MA; Muñoz Velandia OM
Diabetes Metab Syndr; 2021; 15(3):649-653. PubMed ID: 33813236
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend.
Gómez AM; Henao DC; Imitola A; Muñoz OM; Sepúlveda MAR; Kattah L; Guerrero JS; Morros E; Llano JP; Jaramillo MG; León-Vargas F
Endocrinol Diabetes Nutr (Engl Ed); 2018 Oct; 65(8):451-457. PubMed ID: 29914817
[TBL] [Abstract][Full Text] [Related]
34. Predictive Low Glucose Suspend Algorithm in Real Life: A Five-Year Follow-Up Retrospective Analysis.
Tubili C; Pollakova D; Nardone MR; Di Folco U
J Diabetes Sci Technol; 2021 Nov; 15(6):1303-1307. PubMed ID: 32865016
[TBL] [Abstract][Full Text] [Related]
35. Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort.
Müller L; Habif S; Leas S; Aronoff-Spencer E
Diabetes Technol Ther; 2019 Sep; 21(9):478-484. PubMed ID: 31329468
[No Abstract] [Full Text] [Related]
36. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
[TBL] [Abstract][Full Text] [Related]
37. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
[TBL] [Abstract][Full Text] [Related]
38. Intermittent Scanning Glucose Monitoring or Predicted Low Suspend Pump Treatment: Does It Impact Time in Glucose Target and Treatment Preference? The QUEST Randomized Crossover Study.
Schierloh U; Aguayo GA; Schritz A; Fichelle M; De Melo Dias C; Vaillant MT; Cohen O; Gies I; de Beaufort C
Front Endocrinol (Lausanne); 2022; 13():870916. PubMed ID: 35712259
[TBL] [Abstract][Full Text] [Related]
39. Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort With Diabetes Mellitus Pre/Post Tandem Basal-Iq Technology Remote Software Update.
Pinsker JE; Leas S; Müller L; Habif S
Endocr Pract; 2020 Jul; 26(7):714-721. PubMed ID: 33471639
[TBL] [Abstract][Full Text] [Related]
40. The Medtronic 780G advanced hybrid closed-loop system achieves and maintains good glycaemic control in type 1 diabetes adults despite previous treatment.
Quirós C; Alonso-Carril N; Rodríguez-Rodríguez S; Barahona MJ; Orois A; Simó-Servat A; Ramos M; Perea V
Endocrinol Diabetes Nutr (Engl Ed); 2023 Feb; 70(2):130-135. PubMed ID: 36925230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
